It is well known that in the treatment of type 1 diabetes mellitus (T1DM), continuous subcutaneous insulin infusion (CSII) by pump systems results in marked advantages compared to multiple daily injections (MDI) [1–6]. This evidence concerns the gene INS and type 1 diabetes mellitus.